Skip to main content
Premium Trial:

Request an Annual Quote

Bayer Pharma Head Tapped to Replace Oxford GlycoSciences CEO

NEW YORK, May 24 - Oxford GlycoSciences today said it has hired David Ebsworth to take over the CEO post after Michael Kranda leaves on July 11.

Ebsworth, 47, will be "CEO Designate" and formally begin on July 1, according to OGS. He will work alongside Kranda, who cited family reasons for his departure.


The new CEO comes to OGS from Bayer, where he ran its worldwide pharmaceutical business. Before that he was president of the German giant's North American pharmaceutical division.


Click here for more information.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.